Related references
Note: Only part of the references are listed.FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma Is FTY720 the next autophagy-blocking agent in lymphoma treatment?
Lapo Alinari et al.
AUTOPHAGY (2012)
Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells
Giovanni Reddiconto et al.
BLOOD (2012)
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide
Dennis J. Goussetis et al.
BLOOD (2012)
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
Parvathi Ranganathan et al.
BLOOD (2012)
Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model
Yoanne Mousseau et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
Florian H. Heidel et al.
CELL STEM CELL (2012)
Reactivating PP2A by FTY720 as a Novel therapy for AML with C-KIT tyrosine kinase domain mutation
Yan Yang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
E. Traer et al.
LEUKEMIA (2012)
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
E. Weisberg et al.
LEUKEMIA (2012)
Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia
Angelo Michele Carella et al.
LEUKEMIA & LYMPHOMA (2012)
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Oliver Hantschel et al.
NATURE CHEMICAL BIOLOGY (2012)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma
Adriana Estrada-Bernal et al.
NEURO-ONCOLOGY (2012)
Targeting Epigenetic Readers in Cancer
Mark A. Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
FTY720 Suppresses Liver Tumor Metastasis by Reducing the Population of Circulating Endothelial Progenitor Cells
Chang Xian Li et al.
PLOS ONE (2012)
Role of the promyelocytic leukaemia protein in cell death regulation
P. Salomoni et al.
CELL DEATH & DISEASE (2012)
A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia
Yaoyu Chen et al.
BLOOD (2011)
Δ12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice
Shailaja Hegde et al.
BLOOD (2011)
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
Bengt Simonsson et al.
BLOOD (2011)
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression
Claire M. Lucas et al.
BLOOD (2011)
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
Amr R. Ibrahim et al.
BLOOD (2011)
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study
Paolo Gallipoli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Immune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia A Randomized Trial of Frontline High-Dose Imatinib Mesylate With or Without Pegylated Interferon Alpha-2b and Granulocyte-Macrophage Colony-Stimulating Factor
Jorge Cortes et al.
CANCER (2011)
Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 - a novel Wnt/β-catenin signaling inhibitor
Rina Nagao et al.
CANCER LETTERS (2011)
Sphingosine Kinase Inhibitors and Cancer: Seeking the Golden Sword of Hercules
Susan Pyne et al.
CANCER RESEARCH (2011)
Autophagy: Renovation of Cells and Tissues
Noboru Mizushima et al.
CELL (2011)
Canonical Wnt Signaling Regulates Hematopoiesis in a Dosage-Dependent Fashion
Tiago C. Luis et al.
CELL STEM CELL (2011)
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
The dynamic nature of autophagy in cancer
Alec C. Kimmelman
GENES & DEVELOPMENT (2011)
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
Christian Hurtz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo
K. Schuster et al.
BLOOD CANCER JOURNAL (2011)
Fish consumption and prostate cancer risk a review and meta-analysis
Konrad M. Szymanski et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2010)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P. Hughes et al.
BLOOD (2010)
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Sophie Park et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML
Yingzi Wang et al.
SCIENCE (2010)
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study
Francis J. Giles et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
Genetic Interaction of PGE2 and Wnt Signaling Regulates Developmental Specification of Stem Cells and Regeneration
Wolfram Goessling et al.
CELL (2009)
15d-PGJ(2) Induces Apoptosis by Reactive Oxygen Species-mediated Inactivation of Akt in Leukemia and Colorectal Cancer Cells and Shows In vivo Antitumor Activity
Sung-Won Shin et al.
CLINICAL CANCER RESEARCH (2009)
The Double-Edged Sword of Autophagy Modulation in Cancer
Eileen White et al.
CLINICAL CANCER RESEARCH (2009)
Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph plus ALL and CML cells in vitro
Brigitte Kircher et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
Cristian Bellodi et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
The Human Promyelocytic Leukemia Protein Is a Tumor Suppressor for Murine Skin Carcinogenesis
Victoria M. Virador et al.
MOLECULAR CARCINOGENESIS (2009)
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia
Y. Hu et al.
LEUKEMIA (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Chen Zhao et al.
NATURE (2009)
IFNα activates dormant haematopoietic stem cells in vivo
Marieke A. G. Essers et al.
NATURE (2009)
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Yaoyu Chen et al.
NATURE GENETICS (2009)
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients
A. K. Samanta et al.
ONCOGENE (2009)
A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia
Qun-Ye Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Yun Dai et al.
BLOOD (2008)
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
Duane C. Hassane et al.
BLOOD (2008)
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation
Christine Dierks et al.
CANCER CELL (2008)
Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells
Geoffrey L. Uy et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis
Kirsteen H. Maclean et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Linhua Jin et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells
E. Bonhoure et al.
LEUKEMIA (2008)
PML targeting eradicates quiescent leukaemia-initiating cells
Keisuke Ito et al.
NATURE (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia
C. Sillaber et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo
Chen Zhao et al.
CANCER CELL (2007)
The role of interferon-alpha in the treatment of chronic myeloid leukemia
Lisa A. Kujawski et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2007)
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
Paolo Neviani et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Bcr-abl-independent imatinib-resistant k562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors
Sang Min Lee et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells
Yusuf Baran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Upregulation of the TGFβ signalling pathway by Bcr-Abl:: Implications for haemopoietic cell growth and chronic myeloid leukaemia
Gigi M. O. Moller et al.
FEBS LETTERS (2007)
Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation
Addolorata Maria Luce Coluccia et al.
EMBO JOURNAL (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Warren Fiskus et al.
BLOOD (2006)
Janus kinase 2: A critical target in chronic myelogenous leukemia
Ajoy K. Samanta et al.
CANCER RESEARCH (2006)
Oncogenic PI3K deregulates transcription and translation
AG Bader et al.
NATURE REVIEWS CANCER (2005)
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
P Neviani et al.
CANCER CELL (2005)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert et al.
LEUKEMIA (2005)
A Cxcl12-Cxcr4 chemokine signaling pathway defines the initial trajectory of mammalian motor axons
I Lieberam et al.
NEURON (2005)
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells
A Burgess et al.
ONCOGENE (2004)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway
K Keeshan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Phosphoinositide 3-kinase signalling - which way to target?
MP Wymann et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxarmic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
R Nimmanapalli et al.
BLOOD (2003)
Jak2 is involved in c-Myc induction by Bcr-Abl
SH Xie et al.
ONCOGENE (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
S Branford et al.
BLOOD (2002)
Interferon-alpha in tumor immunity and immunotherapy
F Belardelli et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation
SH Xie et al.
ONCOGENE (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Role of promyelocytic leukemia (PML) protein in tumor suppression
EM Rego et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine
J Taipale et al.
NATURE (2000)
Share Paper
